

PATENT APPLICATION File No.: 00-22

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R.

Presnell, Richard D. Holly, Andrew J. Nelson

Serial No.:

09/825,561

Group Art Unit:

Filed:

April 3, 2001 Examiner:

For:

SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

### RESPONSE TO NOTICE TO FILE MISSING PARTS

Box Missing Parts Commissioner for Patents Washington, DC 20231

Sir:

It is respectfully submitted herewith the Combined Declaration and Power of Attorney signed and dated by Applicants for the above-captioned application. This submission is in response to the Notice to File Missing Parts dated July 17, 2001 (a copy thereof is attached hereto) and is being filed within two months of the date of the letter.

Also submitted herewith are a corrected sequence listing and a substitute sequence listing diskette. This submission is in response to the aforementioned Notice to File Missing Parts dated July 17, 2001.

In each case the sequences were designated "Artificial Sequence." Explanation of the source of genetic material is required (sections <220> to <223>), but was mistakenly omitted or incorrect. The changes, per the Sequence Listing Error Summary, Item 11, (attached to Notice to File Missing Parts dated July 17, 2001), were made in accordance with the sequence listing rule 37 CFR §1.823, and with support in the originally filed application as follows:

- SEQ ID NO. 16 Supported in SEQ ID NO. 15
- SEQ ID NO. 18 Supported in SEQ ID NO. 17
- SEQ ID NO. 30 Supported in SEQ ID NO. 29
- SEQ ID NO. 31 was incorrectly denoted an "artificial sequence" when it is a
  "Homo sapiens" sequence. This error was corrected. Support for the denoting
  SEQ ID NO. 31 as Homo sapiens is found in the specification on page 98
  (Example 8) and SEQ ID NO. 1
- SEQ ID NO. 73 Supported in SEQ ID NO. 72

These changes are supported in the originally filed application and hence include no new matter.

The content of the above-captioned application and the computer readable copy is the same and, where applicable, includes no new matter as required by 37 CFR 1.821-1.825.

Applicants claim small entity status. Please charge the total fee, estimated to be \$65.00, to ZymoGenetics, Inc., Deposit Account No. 26-0290. A duplicate of this sheet is enclosed.

Respectfully submitted,

Johnifer K. Johnson, J.D. Registration No. 43,696









## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Cindy A. Sprecher, Julia E. Novak, James W. West, Scott R.

Presnell, Richard D. Holly, Andrew J. Nelson

Serial No.:

09/825,561

Group Art Unit:

Filed:

April 3, 2001 Examiner:

For:

SOLUBLE ZALPHA11 CYTOKINE RECEPTORS

## **CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Box Missing Parts Commissioner for Patents Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Return Postcard

2. Response to Notice to File Missing Parts (in duplicate)

3. Copy of Notice to File Missing Parts

4. Executed Combined Declaration and Power of Attorney

5. Paper Copy of Corrected Sequence Listing (76 pages)

6. Substitute Sequence Listing Diskette compliant with 37 CFR 1.821-1.825

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box Missing Parts Commissioner for Patents Washington, DC 20231

on September 12, 2001.

Marianne Carello

*.*\*



**CONFIRMATION NO. 2838** 

FORMALITIES LETTER
\*OC000000006306097\*

Jennifer K. Johnson, J.D. ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle, WA 98102

Date Mailed: 07/17/2001

#### NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

#### FILED UNDER 37 CFR 1.53(b)

#### Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is unsigned.
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$65 for a small entity in compliance with 37 CFR 1.27, must be submitted with the missing items identified in this letter.
- The balance due by applicant is \$ 65.
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of
  the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as
  indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
  substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content
  of the sequence listing information recorded in computer readable form is identical to the written (on paper
  or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR
  1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

09825561

# A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE